Spatial and dosimetric evaluation of residual distortions of prostate and seminal vesicle bed after image-guided definitive and postoperative radiotherapy of prostate cancer with endorectal balloon

Sabine Levegrün | Christoph Pöttgen | Konstantinos Xydis | Maja Guberina | Jehad Abu Jawad | Martin Stuschke

Department of Radiotherapy, University Hospital Essen, Essen, Germany

Abstract

**Purpose:** To quantify daily residual deviations from the planned geometry after image-guided prostate radiotherapy with endorectal balloon and to evaluate their effect on the delivered dose distribution.

**Methods:** Daily kV-CBCT imaging was used for online setup-correction in six degrees of freedom (6-dof) for 24 patients receiving definitive (12 RTdef patients) or postoperative (12 RTpostop patients) radiotherapy with endorectal balloon (overall 739 CBCTs). Residual deviations were evaluated using several spatial and dosimetric variables, including: (a) posterior Hausdorff distance \( \text{HD}_{\text{post}} \) (=maximum distance between planned and daily CTV contour), (b) point \( P_{\text{worst}} \) with largest \( \text{HD}_{\text{post}} \) over all fractions, (c) equivalent uniform dose using a cell survival model \( \text{EUD}_{\text{SF}}^\text{plan} \) and the generalized EUD concept \( g\text{EUD}_a \) with parameter \( a = -7 \) and \( a = -20 \). EUD values were determined for planned \( \text{EUD}_{\text{SF}}^\text{plan} \), daily \( \text{EUD}_{\text{SF}}^\text{ind} \), and delivered dose distributions \( \text{EUD}_{\text{SF}}^\text{accum} \) for plans with 6 mm (=clinical plans) and 2 mm CTV-to-PTV margin. Time series analyses of interfractional spatial and dosimetric deviations were conducted.

**Results:** Large \( \text{HD}_{\text{post}} \) values \( \geq 12.5 \) mm \( (\geq 15 \) mm) were observed in 20/739 (5/739) fractions distributed across 7 (3) patients. Points \( P_{\text{worst}} \) were predominantly located at the posterior CTV boundary in the seminal vesicle region (16/24 patients, 6/7 patients with \( \text{HD}_{\text{post}} \geq 12.5 \) mm). Time series analyses revealed a stationary white noise characteristic of \( \text{HD}_{\text{post}} \) and relative dose at \( P_{\text{worst}} \). The \( \text{EUD}_{\text{SF}} \) difference between planned and accumulated dose distributions was <5.4% for all 6-mm plans. Evaluating 2-mm plans, \( \text{EUD}_{\text{SF}} \) deteriorated by <10% (<5%) in 75% (58.5%) of the patients. \( \text{EUD}_{\text{SF}}^\text{accum} \) was well described by the median value of the \( \text{EUD}_{\text{SF}}^\text{ind} \) distribution. PTV margin calculation at \( P_{\text{worst}} \) yielded 8.8 mm.

**Conclusions:** Accumulated dose distributions in prostate radiotherapy with endorectal balloon are forgiving of considerable residual distortions after 6-dof patient setup if they are observed in a minority of fractions and the median value of \( \text{EUD}_{\text{SF}}^\text{ind} \)
determined per fraction stays within 95% of prescribed dose. Common PTV margin calculations are overly conservative because after online correction of translational and rotational errors only residual deformations need to be included. These results provide guidelines regarding online navigation, margin optimization, and treatment adaptation strategies.

**KEY WORDS**

accumulated dose distributions, image-guided radiotherapy, prostate cancer, residual distortions, time series

## 1 | INTRODUCTION

Advanced radiotherapy hardware and software solutions enable daily image guidance for online patient position correction and, in addition, allow the evaluation of residual deviations by means of deformable image registrations and dose summation tools with the purpose of comparing planned and actually delivered dose distributions and optimizing PTV margins. Prostate cancer is a site particularly prone to interfraction motion and distortions, and the choice of posterior margins critically affects rectal toxicity.

The application of an endorectal balloon in prostate radiotherapy has been associated with a number of advantages. Endorectal balloons have been shown to decrease the rectal and anal wall volumes being irradiated to intermediate and high doses by pushing the lateral and posterior rectal wall out of the high-dose region. This was associated with a lower incidence of late rectal toxicity. In addition, an endorectal balloon reduced interfraction prostate motion. On the other hand, the use of endorectal balloons may affect the geometrical accuracy of treatment delivery. Studies using balloon-type endorectal MRI coils demonstrated that endorectal balloons can cause deformations of the prostate. Moreover, analyses of the interfraction variability in endorectal balloon placement relative to the prostate or bony landmarks reported substantial deviations in shape and position from the nominal geometry. The intra- and interindividual dosimetric consequences of such residual deformations and repositioning inaccuracies on the delivered dose distributions in prostate radiotherapy with endorectal balloon are subject of this paper.

We have analyzed a cohort of prostate cancer patients who received definitive or postoperative image-guided radiotherapy (IGRT) with endorectal balloon. Image guidance was based on daily kV cone beam CTs (CBCT) acquired before treatment and subsequent online position correction with a six degrees of freedom (6-dof) couch using a standardized matching region of interest. The aim was to determine the resulting geometrical accuracy of the CTV position in each treatment fraction and to quantify dosimetric consequences of residual deviations from the planned geometry on the delivered dose distribution using deformable image registrations and dose accumulation. In addition, we evaluated the development of residual interfractional distortions as function of time over the course of treatment. Finally, we assessed the size of the posterior CTV-to-PTV margin required to assure an adequate dose coverage of the prostate according to both spatial and dosimetric criteria.

## 2 | METHODS

### 2.A | Patient dataset

#### 2.A.1 | Patient characteristics

The dataset included 24 prostate cancer patients who received definitive radiotherapy (RTdef, 12 consecutive patients, denoted by patient numbers 1–12) or were treated after prostatectomy for PSA recurrence or with adjuvant radiotherapy in case of positive resection margins (RTpostop, 12 consecutive patients, denoted by patient numbers 101–112). This retrospective study was approved by the ethics committee of our institution.

#### 2.A.2 | Treatment planning

Computer tomography (CT) imaging for treatment planning was acquired in supine position with emptied rectum and half-filled urinary bladder (approx. 200 ml). All patients were imaged and treated with an endorectal balloon fabricated in-house in two sizes (small: 10 cm length, 3.6 cm diameter, 23 patients; large: 13.5 cm length, 4.6 cm diameter, 1 patient). Prior to CT imaging and each fraction, the endorectal balloon was covered with anesthesia gel, manually inserted and inflated to a prescribed fill volume of 75 ml (small size) or 125 ml air (large size) using a 50 ml syringe. The endorectal balloon was then gently retracted towards the anal canal.

Treatment planning was performed in Eclipse (V15.5, Varian Medical Systems, Palo Alto, CA, USA). All patients were treated with 6 or 8 MV photons using a volumetric modulated arc therapy technique (RapidArc, Varian Medical Systems, Palo Alto, CA, USA) with two counter-rotating arcs.

RTdef patients received a total dose of 78 Gy delivered in 39 fractions (5 × 2 Gy per week) to the CTV containing the prostate and base of the seminal vesicles. RTpostop patients were treated to 68 Gy delivered in 34 fractions of 2 Gy or to 68.4 Gy in 38 fractions of 1.8 Gy. When an initial CTV1 was treated which included the seminal vesicles or seminal vesicle base followed by a second series excluding the seminal vesicles in CTV2, only CTV1 was analyzed.
The PTV was calculated as CTV expansion by 6 mm posteriorly and 8 mm in anterior and lateral direction.

2.A.3 | Treatment delivery and daily image guidance

Treatments were delivered at a Novalis TrueBeam linac (Varian Medical Systems, Palo Alto, CA, USA; BrainLAB AG, Feldkirchen, Germany) equipped with a 6-dof Perfect Pitch couch top. Prior to each fraction, a low-dose CBCT was recorded with acquisition parameters optimized to balance image quality and dose with preponderance of high contrast structures, i.e. bones and the air-filled endorectal balloon (X-ray tube current: 25 mA, voltage: 125 kV, exposure: 335 mAs, exposure time: 13.425 s, full arc, CTDI value: 4.5 mGy, 2 mm slice thickness, 512 × 512 image matrix). A rigid 6-dof registration between planning CT and CBCT was performed automatically using a rectangular region of interest comprising the anterior half of the endorectal balloon posteriorly, the symphysis anteriorly, the periprostatic tissue and the obturator internus muscle laterally, the seminal vesicles superiorly, and the penile bulb inferiorly (“online match”). The obtained 6-dof correction vector was used for online adjustment of the patient position using the treatment couch.

Patients received on average 30.8 CBCTs during treatment (range: 23–37 CBCTs per patient). The 12 RT_{def} patients had 346 CBCTs (range: 23–33 CBCTs per patient). The 12 RT_{postop} patients had 393 CBCTs (range: 28–37 CBCTs). In total, 739 CBCTs were analyzed.

2.B | Data analysis

To assess residual setup errors not correctable by rigid registration, deformable image registrations were performed offline between the planning CT (i.e., reference image) and each CBCT (i.e., target image). The deformable image registration software implemented in Eclipse uses a modified, accelerated demons algorithm.^{13,14} Each deformable registration was based on the rigid registration of the online match. To assess the daily variation in patient anatomy, the resulting registration vector field was used after visual inspection to propagate the planned CTV contour from the planning CT to each of the n CBCTs performed per patient, yielding contours CTV_{CBCTi} (i = 1…n). The CTV_{CBCTi} contours were then rigidly copied back to the planning CT using the online match for further analysis.

2.B.1 | Spatial evaluations

For every patient, the union CTV_{acc} of CTV_{plan} and all CTV_{CBCTi} was calculated. To evaluate how far the daily CTV_{CBCTi} contours projected beyond CTV_{plan}, a series of evaluation PTVs was generated with isotropic margins of 2 to ≥20 mm (step width 1 mm) around CTV_{plan} (PTV_{iso}^{min}), and shells of 1 mm width were derived. To geometrically assess the dislocation of the daily CTV contour, the absolute volume of each CTV_{CBCTi} outside of PTV_{iso}^{min} (x = 2…≥20 mm) was determined. From these data, we derived for all patients and every fraction the Hausdorff distance HD_{iso} (superscript iso: isotropic), i.e. the largest of all the distances from a point on CTV_{plan} to the closest point on CTV_{CBCTi} as a measure of the maximum shift of the daily CTV with respect to CTV_{plan}. Because the posterior CTV margin is of particular interest regarding rectal toxicity, we separately evaluated the dislocation of the daily CTV contour towards the rectum by determining the absolute volume of each CTV_{CBCTi} outside of PTV_{iso}^{min} in the overlap region between CTV_{CBCTi} and the rectum contour expanded by 5 mm. The corresponding Hausdorff variable was named HD_{post} (superscript post: posterior).

For every patient, several points of interest were defined: one point at the center of CTV_{plan} (P_0), 4-6 points at the posterior periphery of the prostate or in the seminal vesicle region (P_i, i = 1…6), plus the point in CTV_{plan} causing the maximum HD_{post} value over all fractions (denoted by P_{worst}). In each case, a small 3D structure was contoured in Eclipse whose center-of-mass defined the point. The points of interest were propagated to each CBCT_{i} using the calculated deformable image registrations. The deformation vector components in left-right direction (x-component), anterior-posterior direction (y-component), and superior-inferior direction (z-component) at these points were analyzed.

PTV margins were calculated using the recipe proposed by van Herk:^{15} To ensure a minimum dose to the CTV of 95% for 90% of the patients, a CTV-to-PTV margin of 2.5 Σ+1.64σ_i–1.64σ_p, where Σ denotes the total standard deviation (SD) of preparation (systematic) errors, σ_i the total SD of execution (random) errors combined with the penumbra width, and σ_p the SD describing the penumbra width, and σ_p^2 = σ_i^2 + σ_p^2.

2.B.2 | Dosimetric evaluations

Because the workflow for accumulation of full dose distributions over a treatment series is not supported by Eclipse, the dose delivered to selected points of interest per fraction was determined to enable dose summation at these points. For that purpose, the fraction dose at each point was derived from the dose at its displaced position obtained with the calculated deformation vector field. All dose values were normalized to the planned dose at the respective point (denoted by D_{plan}). Point P_{worst} was analyzed for all 24 patients, points P_0 and P_i were investigated for the four patients with the worst HD_{post} distributions (called worst HD_{post} patients). Posterior dose gradients were measured in each patient’s treatment plan from the PTV periphery up to 7 mm towards the posterior rectal wall, at a height midway between base and apex of the prostate CTV.

To facilitate full dose accumulation over the treatment series, 15 patients were transferred to the software package MIM (V6.9.6, MIM Software Inc., Cleveland, OH, USA), which allows dose accumulation based on the planned dose distribution and the deformable image registrations calculated in Eclipse. For data selection, patients were ranked according to the maximum HD_{post} value in their treatment series and the 50%-95% quantiles of the HD_{post} distribution. All eight patients in the worst-performing third were selected plus 5/8 and 2/8 randomly selected patients in the intermediate-performing
and best-performing third, respectively, yielding 15 patients with 454 CBCTs. Within MIM, dose accumulation over the series of CBCTs was performed assuming the validity of the static dose cloud approximation. The planned dose distribution was first rigidly copied to each CBCT, using the Eclipse online match and then deformably warped back to the planning CT using the deformable image registrations calculated in Eclipse. Subsequently, the dose contributions from each CBCT were summed up in the planning CT. Dose volume histograms (DVH) of CTV$_{\text{plan}}$ for the original clinical dose distribution and the accumulated dose distribution accounting for deformations over the treatment series as well as CTV$_{\text{CBCT}}$/DVHs of the individual fractions were exported for further analysis.

In addition to the clinical plans with 6 mm posterior margin, supplementary plans based on an isotropic 2 mm CTV-to-PTV margin were retrospectively optimized for the same treatment technique and constraints as the clinical plans and analyzed to investigate the effect of a reduced margin. This study included 12 patients with 364 CBCTs (8/2/2 patients in the worst-/intermediate-/best-performing third, respectively).

To quantify dosimetric consequences of any dose deviations from the planned dose distribution, the concept of equivalent uniform dose (EUD)$^{17}$ was applied using two different approaches: (a) The original EUD model$^{17}$ based on clonogen survival (EUD$_{\text{SF}}$) with parameter values SF$_2$ = 0.6 for the surviving fraction of clonogenic cells at 2 Gy and a/β = 2 Gy for the fractionation sensitivity of prostate cancer.$^{18,19}$ This was equivalent to a tumor control probability of 80% for a tumor consisting of $10^8$ clonogenic cells$^{20}$ irradiated to a total dose of 78 Gy delivered with 2 Gy per fraction. For the EUD calculations, the dose distributions were normalized to 78 Gy (2 Gy per fraction) at the prescription point. (b) The phenomenological power law model as generalized concept of EUD (gEUD)$^{21,22}$ with two choices of the tissue-specific parameter a = $-7$ (gEUD$_{\text{as}}$) and a = $-20$ (gEUD$_{\text{as}}$). EUD values were determined for planned (EUD$_{\text{EUD}}$), daily (EUD$_{\text{ind}}$), and accumulated dose distributions (EUD$_{\text{accum}}$), respectively.

2.B.3 | Time series analyses

To investigate the variation of daily residual deviations from the treatment plan as function of time over the course of treatment, time series analyses were performed. Both spatial (posterior displacement of point $P_{\text{worst}}$; HD$^{\text{post}}$) and dosimetric (D$_{\text{iso}}$ at $P_{\text{worst}}$) variables were evaluated for the four worst HD$^{\text{post}}$ patients. The time series analyses were performed in SAS (version 14.1, SAS Institute, Cary, NC, USA). Nonstationary or random walk was tested using an augmented Dickey-Fuller unit root test based on an autoregressive model with a single mean and time trend (rho statistic). To search for any similarity between observations as a function of the time lag between them, positive or negative first to fourth order autocorrelation in the time series was analyzed by means of the Durban-Watson statistic (Proc AUTOREG). Bartlett’s Kolmogorov-Smirnov test statistic was applied to test the white noise hypothesis (Proc SPECTRA). Outliers (i.e. shock signatures) in the time series which could not be accounted for by the estimated model were detected using an autoregressive integrated moving average (ARIMA) model of fourth order at $\alpha = 0.001$ (Proc ARIMA).

2.C | Statistical analysis

Statistical analyses were performed in SAS (version 14.1, SAS Institute, Cary, NC, USA) and SPSS Statistics (version 22, IBM, Armonk, NY, USA). All statistical tests and procedures used are specified together with the results. P-values were two-sided, and $P < 0.05$ was considered statistically significant.

3 | RESULTS

3.A | Size of planned and accumulated volumes

For the 24 patients, the average size of CTV$_{\text{plan}}$, CTV$_{\text{acc}}$, and PTV amounted to $91.5 \pm 6.2 \text{ cm}^3$ (mean $\pm$ S.E.M.), $154.7 \pm 10.5 \text{ cm}^3$, and $237.9 \pm 10.9 \text{ cm}^3$, respectively. On average, CTV$_{\text{acc}}$ was larger by a factor of 1.73 $\pm$ 0.06 than CTV$_{\text{plan}}$. The PTV was larger by a factor of 1.61 $\pm$ 0.07 than CTV$_{\text{acc}}$. An average CTV$_{\text{CBCT}}$ volume of $3.13 \pm 0.19 \text{ cm}^3$ ($0.84 \pm 0.09 \text{ cm}^3$) was per fraction outside of PTV$_{\text{2mm}}$ (PTV$_{\text{6mm}}$). In the posterior direction, an average fractional CTV$_{\text{CBCT}}$ volume of $1.26 \pm 0.10 \text{ cm}^3$ ($0.36 \pm 0.05 \text{ cm}^3$) was outside of PTV$_{\text{2mm}}$ (PTV$_{\text{6mm}}$).

RT$_{\text{postop}}$ patients had significantly larger CTV$_{\text{plan}}$ and CTV$_{\text{acc}}$ volumes than RT$_{\text{def}}$ patients. Also the CTV$_{\text{CBCT}}$ volume outside of PTV$_{\text{2mm}}$ (PTV$_{\text{6mm}}$) was larger, both isotropically and in posterior direction (cf. comparison of RT$_{\text{def}}$ and RT$_{\text{postop}}$ patients in Table S1). PTV size, bladder and endorectal balloon volumes were not different in the two patient groups.

3.B | Spatial considerations

Empirical distribution functions of HD$^{\text{post}}$ determined for every fraction of the RT$_{\text{def}}$ and RT$_{\text{postop}}$ patients are shown in Figs. 1(a) and 1(b), respectively. Figures S1(a)–S1(d) illustrate the variation of HD$^{\text{iso}}$ and HD$^{\text{post}}$ over the treatment series for each individual RT$_{\text{def}}$ and RT$_{\text{postop}}$ Patient. The mean and maximum values of the HD$^{\text{iso}}$ and HD$^{\text{post}}$ distributions per patient are shown in Figs. 2(a) and 2(b), respectively. Additional parameters characterizing the distributions including 50% and 95% quantiles are provided in Table S2. A significant interpatient variability in both the HD$^{\text{iso}}$ and HD$^{\text{post}}$ distributions among all patients was observed ($P < 0.0005$, Kruskal-Wallis test). The median HD$^{\text{iso}}$ values (HD$^{\text{post}}$ values) for RT$_{\text{def}}$ and RT$_{\text{postop}}$ patients amounted to 5.5 mm and 6.5 mm (3.5 mm and 5.5 mm), respectively. The patients with largest 50%-95% quantiles of the HD$^{\text{post}}$ distribution over the treatment series were RT$_{\text{def}}$ patients 7 and RT$_{\text{postop}}$ patients 103, 106, and 110 (denoted as worst HD$^{\text{post}}$ patients).

Table S3 lists the number of fractions in which selected spatial parameters exceeded a given threshold value and quotes across how many patients these fractions were distributed. For example, large
HD\textsuperscript{post} values ≥12.5 mm (≥15 mm) were observed in 37/739 (9/739) fractions distributed across 11 (4) patients. Large HD\textsuperscript{post} values ≥12.5 mm (≥15 mm) occurred in 20/739 (5/739) fractions distributed across 7 (3) patients.

For all RT\textsubscript{def} patients, point P\textsubscript{worst} which caused the maximum HD\textsuperscript{post} value over all fractions was located at the posterior CTV boundary, either in the seminal vesicle region (5/12 patients, 2/5 patients with HD\textsuperscript{post} ≥ 12.5 mm), close to the apex (3/12 patients, no patient with HD\textsuperscript{post} ≥ 12.5 mm) or in an intermediate position (4/12 patients, no patient with HD\textsuperscript{post} ≥ 12.5 mm). For 11/12 RT\textsubscript{postop} patients (4/11 patients with HD\textsuperscript{post} ≥ 12.5 mm), P\textsubscript{worst} was located in the seminal vesicle region. For 1/12 RT\textsubscript{postop} patient (HD\textsuperscript{post} ≥ 12.5 mm), P\textsubscript{worst} was between prostate apex and base.

The anterior-posterior shift at point P\textsubscript{worst} for every fraction of RT\textsubscript{def} and RT\textsubscript{postop} patients is displayed in Figs. S2(a) and S2(b), respectively. The mean and maximum values of each patient’s distribution of the anterior-posterior shift at point P\textsubscript{worst}, assessed using the y-component of the deformation vector at that point, are visualized in Fig. 2(c) and listed in Table 1. Table S4 provides corresponding numbers for the shifts in left-right direction (x-component of the deformation vector) and superior-inferior direction (z-component) as well as additional parameters characterizing the distributions. Shifts of point P\textsubscript{worst} in x, y, and z were weakly correlated over all patients (correlation of y with x: Spearman correlation coefficient $r_s = 0.14$, $P = 0.0001$; correlation of y with z: $r_s = -0.15$, $P = 0.0001$). Deviations in y were larger than in x or z (mean values over all patients
and fractions: $x = 0.78$ mm, SD = 2.59 mm; $y = 1.62$ mm, SD = 4.10 mm; $z = -0.45$ mm, SD = 3.35 mm).

Figures 3(a)–3(d) display the main characteristics of the distributions of the anterior-posterior shift at all specified points of interest in CTV_{plan} over the treatment series for the four worst HD_{post} patients. The numbers are summarized in Table S5. Generally not only the maximum values but also the mean posterior shifts were larger at point P_{worst} than at the other points of interest in the respective patient, except for patient 7, points P_{3} and P_{5}.

Margin calculations\textsuperscript{15} using $\Sigma = 2.98$ mm (SD of mean values per patient), $\sigma = 2.76$ mm (SD of $y$ per patient around the mean), and $\sigma_p = 4.12$ mm (cf. section 3.C. Dosimetric considerations), hence $\sigma' = 4.96$ mm, derived from our data, yielded a posterior PTV margin of 8.8 mm (9.7 mm) required to ensure a minimum dose in the CTV of 95\% for 90\% (95\%) of our patients.

3.C | Dosimetric considerations

Figures S2(c) and S2(d) visualize the relative dose at point P_{worst} for every treatment fraction of the RT_{def} and RT_{postop} patients, respectively. Characteristics of each patient’s $D_{rel}$ distribution over the treatment series are illustrated in Fig. 2(d) and included in Table 1. Also quoted are EUD_{SF} values which, when constantly applied over the treatment course, would lead to the same cell kill as the actually
delivered, from fraction to fraction varying, dose. EUD_{SF} at P_{worst} did not drop below 1.85 Gy per fraction for any of the patients. For 21/24 patients (87.5%), the decline in EUD_{SF} with respect to the planned value was <$5%.

Figures 3(e)–3(h) present the main parameters of the D_{rel} distributions at all specified points of interest within CTV_{plan} over the treatment series for the four worst HD_{post} patients. Corresponding parameters describing the distributions of dose deviations from the treatment plan over the series are listed in Table S5. For every patient, a significant heterogeneity in the D_{rel} distribution from point to point was observed, indicating that the expectation value for the accumulated dose is not equal at all points.

To investigate dosimetric consequences of daily residual distortions, the dependence of D_{rel} on anterior-posterior and superior-inferior shifts, assessed through the y- and z-components, respectively, of the deformation vector at selected points of interest was evaluated. Regression analysis of all 120 fractions of the four worst HD_{post} patients revealed a substantially stronger dependence of D_{rel} on anterior-posterior shifts compared with superior-inferior shifts (Fig. 4). With increasing posterior shifts, a pronounced drop in D_{rel} was observed, consistent with the expected decline due to the dose gradient measured in each patient’s treatment plan. The posterior dose gradient averaged over all 24 treatment plans amounted to 4.21 ± 0.10% per mm and could be approximated by a gaussian distribution with $\sigma_p = 4.12$ mm. Dose gradients for RT_{def} and RT_{postop} patients were not different ($P = 0.07, F$-test).

Table 2 lists absolute EUD_{SF} and gEUD values calculated using $a = -20$ and $a = -7$ for the original and accumulated dose distributions of the clinical 6 mm plans for 15 patients. Resulting percent EUD differences between original and accumulated dose distributions

---

**Table 1** Parameters summarizing the distributions of the Hausdorff distance, the anterior-posterior deformation vector component y and the relative dose at point P_{worst} over the treatment series as well as EUD_{SF} at P_{worst} for prostate patients treated with definitive (patients 1–12) or postoperative radiotherapy (patients 101–112), respectively.

| Pat No of CBCTs | No of HD_{max} over all fractions | HD_{max}^iso [mm] | Mean [mm] | Sigma [mm] | HD_{max}^post [mm] | Mean [mm] | Sigma [mm] | Max [mm] | Mean Sigma Min EUD SF |
|-----------------|----------------------------------|-------------------|----------|-----------|-------------------|-----------|-----------|---------|---------------------|
| 1               | 30                               | 8.5               | 4.8      | 1.7       | 8.5               | 3.5       | 2.2       | -0.26   | 2.24 83.13 2.056    |
| 2               | 33                               | 8.5               | 3.6      | 1.7       | 4.5               | 1.7       | 0.8       | 0.47    | 1.32 53 2.054      |
| 3               | 27                               | 10.5              | 7.2      | 1.7       | 5.5               | 2.9       | 1.5       | 0.35    | 1.95 3.8          |
| 4               | 28                               | 6.5               | 4.9      | 1.2       | 5.5               | 3.0       | 1.3       | 0.95    | 1.58 3.6          |
| 5               | 27                               | 9.5               | 6.8      | 1.6       | 4.5               | 2.2       | 1.2       | 0.07    | 0.89 1.7          |
| 6               | 31                               | 11.5              | 6.2      | 2.5       | 5.5               | 3.5       | 1.1       | 1.96    | 1.36 5.1          |
| 7               | 23                               | 14.5              | 8.7      | 3.1       | 14.5              | 7.6       | 3.6       | 3.53    | 3.50 12.0        |
| 8               | 27                               | 13.5              | 6.4      | 2.2       | 9.5               | 4.4       | 2.2       | 2.19    | 3.69 9.9          |
| 9               | 30                               | 7.5               | 5.0      | 1.4       | 5.5               | 2.8       | 1.6       | -0.77   | 2.53 6.0          |
| 10              | 30                               | 10.5              | 7.4      | 1.5       | 9.5               | 5.4       | 1.4       | 1.10    | 2.52 5.8          |
| 11              | 30                               | 8.5               | 5.0      | 1.3       | 6.5               | 3.1       | 1.4       | -0.30   | 1.89 5.7          |
| 12              | 30                               | 12.5              | 6.0      | 2.3       | 12.5              | 5.0       | 2.6       | 1.97    | 2.45 7.8          |
| 101             | 37                               | 7.5               | 5.3      | 1.3       | 6.5               | 2.3       | 1.3       | -5.57   | 3.34 6.8          |
| 102             | 28                               | 15.5              | 10.2     | 2.2       | 15.5              | 7.2       | 3.0       | 0.64    | 4.80 9.5          |
| 103             | 33                               | 13.5              | 9.9      | 2.0       | 13.5              | 9.5       | 2.3       | 8.18    | 2.74 13.0         |
| 104             | 31                               | 12.5              | 7.4      | 2.0       | 12.5              | 6.6       | 2.4       | 5.25    | 3.35 13.9         |
| 105             | 31                               | 10.5              | 6.7      | 1.9       | 10.5              | 6.4       | 2.3       | 1.72    | 2.39 5.9          |
| 106             | 33                               | 17.5              | 9.3      | 3.8       | 17.5              | 8.7       | 3.7       | 7.72    | 4.26 18.5         |
| 107             | 36                               | 13.5              | 5.3      | 2.8       | 7.5               | 3.8       | 1.9       | 2.97    | 2.15 7.6          |
| 108             | 34                               | 6.5               | 4.4      | 0.8       | 4.5               | 2.1       | 1.0       | -0.60   | 2.06 3.7          |
| 109             | 33                               | 7.5               | 5.1      | 1.2       | 7.5               | 4.8       | 1.5       | 0.65    | 2.97 7.0          |
| 110             | 31                               | 20.5              | 10.9     | 3.3       | 20.5              | 9.1       | 3.5       | 5.63    | 4.56 19.1         |
| 111             | 33                               | 13.5              | 6.2      | 2.0       | 10.5              | 5.1       | 1.7       | 3.05    | 2.53 10.3         |
| 112             | 33                               | 16.5              | 8.1      | 3.9       | 6.5               | 3.8       | 1.6       | -1.38   | 2.07 4.3          |

Abbreviations: EUD_{SF}, equivalent uniform dose calculated using a cell survival model; HD_{max}, maximum value of the Hausdorff distance between planned and daily CTV over all treatment fractions per patient; iso, isotropic; Positive y-value, posterior shift; post, posterior.
FIG. 3. (a–d) Anterior-posterior shift and (e–h) relative dose at different points of interest within the planned CTV for the four prostate patients with worst distribution of the posterior Hausdorff distance over the treatment series. In each plot, the black circles with error bars represent mean value ± one standard deviation of the distribution. The red squares indicate the maximum posterior shift at each point. The green symbols visualize the minimum values of the relative dose distributions. The dashed horizontal lines correspond to the undisturbed values of the treatment plan.
are included. For the clinical 6-mm plans, the deteriorations in EUD_{SF} were smaller than 5% in 14/15 patients (93.3%). Only 1/15 patient experienced a decline in EUD_{SF} of 5.4%. The drop in gEUD_{a=-20} was smaller than 5% for all 15 patients. As expected, the decline in gEUD_{a=-7} was always smaller than that in gEUD_{a=-20}, since the parameter value a=-7 makes gEUD less sensitive to cold spots in the dose distributions. In general, a strong correlation between EUD_{SF} and gEUD_{a=-20} was observed (12 patients with 364 fractions: Pearson correlation coefficient r_p = 0.986, P < 0.0005; Spearman correlation coefficient r_S = 0.985, P < 0.0005). The correlation between EUD_{SF} and gEUD_{a=-7} was weaker, yet statistically significant (r_p = 0.722, P < 0.0005; r_S = 0.717, P < 0.0005).

Corresponding values of EUD_{SF}, gEUD_{a=-20}, and gEUD_{a=-7} for the original and accumulated dose distributions of 12 plans with 2-mm margin are included in Table 2. In total, 3/12 patients (25%) experienced a decline in EUD_{SF} of >10% between original and accumulated dose distributions. In 7/12 patients (58.3%), EUD_{SF} deteriorated by <5%.

Figure 5(a) shows cumulative distribution functions of EUD_{SF} calculated for each individual treatment fraction of the clinical 6-mm plans for 12 patients (4 RTdef, 8 RTpostop). For every patient, the EUD_{SF} value derived from the accumulated dose distribution is indicated by a circle. For better resolution in the high-dose region, the low-dose part was omitted. The cumulative distribution function with full scale is shown in Fig. S3(a). Figure 5(b) and Figure S3(b) show the corresponding plot for the 2-mm plans of the same patients. The EUD_{SF} values cluster around the median values of the EUD_{SF} distributions. In Fig. 5, the median of each patient’s EUD_{ind}_{SF} distribution is plotted versus the EUD_{SF} value for both 6-mm and 2-mm plans. Corresponding plots based on gEUD_{a=-20} and gEUD_{a=-7} are shown in Figs. S4(a) and (b), respectively. A strong correlation between the median EUD_{ind}_{SF} value and EUD_{SF} was observed (r_p = 0.930, P < 0.0005; r_S = 0.946, P < 0.0005).

![Figure 4](image)

**Fig. 4.** Scatter plots of the relative dose at selected points of interest in the planned CTV plotted versus (a) the anterior-posterior and (b) the superior-inferior shift, assessed by the y- and z-components, respectively, of the deformation vector at the considered point for all 120 fractions of the four worst HDpost patients (patients 7, 103, 106, and 110). Only the points of interest at the posterior periphery of the CTV or in the seminal vesicle region (P) and point P_{worst} were included. The points P_{0} located at the center of the prostate were excluded, yielding 646 entries per plot. Results of the fit of a third degree polynomial to the data are also shown (Solid blue line: fit result; dashed line: 95% prediction limit; area shaded in blue: 95% confidence limits). All terms up to n = 3 were significant.
P < 0.0005), indicating that EUD_{SF}^{\text{accum}} derived from the accumulated dose distribution could well be approximated by the median EUD_{SF}^{\text{ind}} value for every plan.

The total dose at point P_{\text{worst}} derived from the full accumulated dose distributions of all 6-mm and 2-mm plans was between the minimum dose D_{\text{min}} and D_{99} for 15/27 = 55.6%, between D_{\text{min}} and D_{98} for 22/27 = 81.5%, and between D_{\text{min}} and D_{97} for 25/27 = 92.6% of the plans, respectively, indicating that P_{\text{worst}} received a dose close to the minimum value in the accumulated dose distribution.

### 3.D | Time series

The time series of posterior shifts at point P_{\text{worst}} over all fractions are shown in Fig. 7(a) for the four worst HD_{\text{post}}-patients. For all patients, nonstationary or random walk could be rejected (Dickey-Fuller unit root test, rho statistic, P < 0.005). For patients 7, 103, and 106, there was no positive or negative first to fourth order autocorrelation of the posterior deviations around their mean with preceding values in the series (Durban-Watson statistic, Proc AUTO-REG, SAS). For patient 110, a positive second order autocorrelation was found (Durbin-Watson statistic, P = 0.0002). The white noise hypothesis could not be rejected in any of the patients (Bartlett's Kolmogorov-Smirnov test, P > 0.50, Proc SPECTRA, SAS). An additive shock signature in the time series was identified at fraction 9 of patient 110 (Proc ARIMA, SAS).

Very similar results were derived for the time series of HD_{\text{post}} (Fig. S5), with the exception that no autocorrelation was found for patient 110. Specifically, nonstationary or random walk could be

---

### Table 2 Absolute EUD_{SF} and gEUD-values for a = −20 and a = −7 of the original and accumulated dose distributions and resulting EUD differences for clinical treatment plans (6 mm PTV-margin) and plans with 2 mm PTV-margin.

| Pat no | Original dose distribution | Accumulated dose distribution | Difference (original-accumulated) |
|--------|-----------------------------|-------------------------------|----------------------------------|
|        | EUD_{SF} | gEUD_{a=−20} | gEUD_{a=−7} | EUD_{SF} | gEUD_{a=−20} | gEUD_{a=−7} | Δ EUD_{SF} | Δ gEUD_{a=−20} | Δ gEUD_{a=−7} |
| 6 mm-margin (clinical plans) |
| 1      | 78.66   | 78.75  | 78.88  | 78.83  | 78.88  | 78.96  | −0.22 | −0.17 | −0.10 |
| 5      | 78.25   | 78.32  | 78.42  | 78.52  | 78.55  | 78.60  | −0.35 | −0.30 | −0.23 |
| 7      | 78.41   | 78.44  | 78.49  | 77.90  | 77.97  | 78.06  | 0.66  | 0.61  | 0.54  |
| 8      | 78.42   | 78.47  | 78.55  | 78.47  | 78.49  | 78.53  | −0.06 | −0.03 | 0.02  |
| 10     | 78.95   | 79.01  | 79.08  | 79.02  | 79.06  | 79.10  | −0.09 | −0.06 | −0.03 |
| 12     | 79.78   | 79.83  | 79.90  | 79.88  | 79.90  | 79.93  | −0.13 | −0.09 | −0.03 |
| 102    | 78.69   | 78.81  | 78.99  | 78.18  | 78.35  | 78.59  | 0.66  | 0.58  | 0.51  |
| 103    | 79.04   | 79.19  | 79.41  | 77.25  | 78.02  | 79.00  | 2.26  | 1.47  | 0.52  |
| 104    | 79.60   | 79.77  | 80.00  | 75.27  | 76.57  | 79.22  | 5.43  | 4.01  | 0.97  |
| 105    | 78.80   | 78.88  | 78.98  | 78.89  | 78.92  | 78.98  | −0.10 | −0.06 | 0.00  |
| 106    | 79.06   | 79.16  | 79.31  | 78.20  | 78.42  | 78.72  | 1.10  | 0.93  | 0.74  |
| 108    | 78.40   | 78.49  | 78.62  | 78.62  | 78.66  | 78.72  | −0.27 | −0.22 | −0.13 |
| 109    | 78.76   | 78.87  | 79.04  | 78.89  | 78.97  | 79.08  | −0.16 | −0.12 | −0.05 |
| 110    | 78.30   | 78.41  | 78.59  | 78.06  | 78.20  | 78.41  | 0.31  | 0.27  | 0.23  |
| 111    | 78.85   | 78.95  | 79.09  | 78.46  | 78.65  | 78.89  | 0.50  | 0.38  | 0.25  |
| 2 mm-margin |
| 1      | 78.66   | 78.74  | 78.85  | 76.90  | 77.54  | 78.36  | 2.25  | 1.52  | 0.63  |
| 5      | 78.72   | 78.77  | 78.85  | 77.60  | 77.97  | 78.38  | 1.42  | 1.02  | 0.60  |
| 7      | 78.48   | 78.52  | 78.58  | 74.23  | 74.82  | 76.07  | 5.41  | 4.72  | 3.19  |
| 12     | 78.73   | 78.76  | 78.81  | 77.50  | 77.74  | 78.04  | 1.56  | 1.29  | 0.98  |
| 102    | 79.07   | 79.15  | 79.26  | 75.36  | 76.21  | 77.73  | 4.69  | 3.71  | 1.93  |
| 103    | 79.25   | 79.45  | 79.74  | 66.19  | 63.59  | 77.13  | 16.48 | 19.96 | 3.28  |
| 104    | 78.65   | 78.77  | 78.96  | 75.34  | 76.33  | 78.10  | 4.20  | 3.10  | 1.10  |
| 105    | 78.53   | 78.59  | 78.67  | 69.04  | 69.06  | 76.40  | 12.09 | 12.12 | 2.89  |
| 106    | 78.77   | 78.84  | 78.94  | 73.47  | 74.16  | 77.18  | 6.73  | 5.93  | 2.23  |
| 108    | 78.79   | 78.86  | 78.96  | 78.47  | 78.59  | 78.73  | 0.41  | 0.34  | 0.28  |
| 110    | 78.35   | 78.42  | 78.53  | 74.62  | 75.23  | 76.45  | 4.77  | 4.07  | 2.65  |
| 111    | 78.21   | 78.33  | 78.51  | 70.21  | 70.82  | 75.88  | 10.22 | 9.59  | 3.35  |

Abbreviations: EUD, equivalent uniform dose; EUD_{SF}, EUD calculated using a cell survival model; gEUD, generalized concept of EUD.
rejected for all four patients (Dickey-Fuller unit root test, rho statistic, $P < 0.015$), whereas the white noise hypothesis could not be rejected in any of the patients (Bartlett’s Kolmogorov-Smirnov test, $P > 0.15$). An additive outlier was also observed in the posterior Hausdorff distances at fraction 9 of patient 110.

Figure 7(b) shows the time series of $D_{rel}$ at point $P_{\text{worst}}$ for the worst HD$^\text{post}$ patients. Nonstationary or random walk could be rejected for all patients (Dickey-Fuller unit root test, rho statistic, $P < 0.015$). No positive or negative first to fourth order autocorrelation of the $D_{rel}$ deviations with preceding values in the series was observed (Durban-Watson statistic). The white noise hypothesis could not be rejected in any of the patients (Bartlett’s Kolmogorov-Smirnov test, $P > 0.25$). Additive outliers (at $P = 0.001$) in $D_{rel}$ at $P_{\text{worst}}$ were observed for patient 7 at fraction 4, for patient 106 at fractions 7, 11, and 14, and for patient 110 at fractions 1 and 9, respectively. In addition, temporary level shifts of $D_{rel}$ per fraction were detected for patient 103 beginning at fraction 18 and lasting for three fractions and for patient 110 beginning at fraction 24.

**4 | DISCUSSION**

Daily residual deformations after image-guided definitive and postoperative radiotherapy of prostate cancer with endorectal balloon were quantified using various spatial and dosimetric parameters, and analyzed regarding their effect on the actually delivered dose distribution.

One of the spatial variables used was the Hausdorff distance quantifying the maximum displacement between daily and planned CTV contour. The HD distributions over all fractions, both when analyzed isotropically and restricted to the posterior region, demonstrated a significant interpatient variability, with RT$^\text{postop}$ patients performing worse than RT$^\text{def}$ patients. Substantially large HD$^\text{iso}$ and HD$^\text{post}$ values in one or more fractions were observed for several patients (Table S3; Fig. S1). For the majority of the patients (5/12 RT$^\text{def}$, 11/12 RT$^\text{postop}$), the point $P_{\text{worst}}$ inside CTV$^\text{plan}$, which exhibited the largest displacement over all fractions, was located at the posterior CTV$^\text{plan}$ boundary in the region of the seminal vesicles or seminal vesicle bed. This finding is consistent with other studies.
one patient (patient 104) showed an EUDSF drop of 5.4%. Hence, to quantify the difference between planned and accumulated dose distributions, the EUDSF model based on parameter values a = 0.6 and w/I = 2 Gy were generally very similar to gEUD-values for a = 20. Analyzing the clinical plans with 6-mm margin, the decline in EUDSF between original and accumulated dose distributions was <5% in 14/15 patients (93.3%). Only one patient (patient 104) showed an EUDSF drop of 5.4%. Hence, a posterior 6-mm margin is sufficient to maintain EUDSF above 95% in >93% of our patients. This estimate is conservative, because particularly patients with poor HDpost distribution were selected for the dose accumulation analysis (patient 104 belongs to the worst third). Even for 2-mm plans, EUDSF deteriorated by <10% and <5% in 75% and 58.3% of the patients, respectively. Hence, the accumulated dose distributions turned out to be forgiving of cold spots in individual treatment sessions. Due to the daily deformation of the prostate and resulting shifts in position with respect to the planned geometry, the dose per fraction at every point in the prostate varies over time. Cold spots at the posterior CTV periphery move from fraction to fraction and are therefore washed out over the series. Note that point Pworst is determined by one single fraction experiencing the largest shift during the treatment series and certainly did not receive the minimum dose value at every fraction. Nonetheless, the accumulated dose at Pworst was between Dmin and D98 (D77) for 81.5% (92.6%) of the analyzed patients, indicating that points Pworst, which were identified by geometrical considerations, received a dose very close to the minimum value of the full accumulated dose distributions. These findings demonstrate that spatial and dosimetric results are consistent.

EUDSF of the accumulated dose distribution can well be approximated by the median value of the distribution of the EUDSF values determined per fraction (Figs. 5 and 6). An EUD analysis of individual fractions can therefore serve as simple alternative to assess the actually delivered dose if software for dose accumulation is not available.

Our analysis of interfraction time series data, based on both spatial and dosimetric variables, could exclude nonstationary or random walk and, instead, revealed a white noise characteristic. This finding is in contrast to the intrafraction prostate motion which has been reported to be a random walk.29–31 In general, no autocorrelation, i.e. no similarity between observations as a function of the time lag between them, was observed. Since the time series are stationary, the expectation value is constant over time. However, the white noise amplitude differs significantly from patient to patient. On
average, two outliers not explained by normal theory were observed per patient. To our knowledge, this is the first study that analyzed interfractional time series in prostate cancer.

A number of previous studies analyzed dosimetric consequences of interfractional CTV displacements and deformations by means of dose accumulation to evaluate appropriate PTV margins, based on weekly MV-CBCTs, daily kV-CBCTs, helical MVCTs, or repeat planning CTs. Only in two studies, an endorectal balloon was used. The majority of the studies analyzed patients treated with definitive RT. One study evaluated patients receiving adjuvant RT of the prostate bed after prostatectomy. While a 3-4 mm posterior margin was considered as too small in some studies, it was found adequate in others. However, the direct quantitative comparison of the studies is hindered by the diverse dosimetric criteria which were used to judge target coverage as adequate and the different navigation techniques applied. Qin et al. used \( g_{EUD_{3.0} - 20} \) as dosimetric criterion, as we did, and found that for 4/22 patients \( g_{EUD_{3.0} - 20} \) for the accumulated dose was <95% of the planned \( g_{EUD_{3.0} - 20} \) and fell below 90% for one patient. They concluded that a 3-mm margin was not appropriate to

**FIG. 7.** Time series plots for the four patients with largest HD\(_{post}\) dispersion over all treatment fractions. (a) Posterior deviations and (b) relative dose, respectively, at point \( P_{worst}. \)
compensate residual variations with a daily correction technique. However, none of the above studies investigated residual deviations after full 6-dof IGRT with online correction of both translations and rotations. In contrast to other studies, we evaluated not only the accumulated dose distribution, but also individual treatment fractions to assess their dose contribution, because this may provide guidelines regarding online navigation and adaptation strategies.

For any dose accumulation study, the accuracy of the algorithm to calculate the deformable image registrations is a matter of concern. The Eclipse algorithm which we used was evaluated according to the recommendations of the AAPM Task Group No. 132. Moreover, the registration results have been visually inspected by an experienced radiation oncologist. Our particular setting is favorable because the low density inside the air-filled endorectal balloon provides a strong contrast with respect to the surrounding soft tissue in planning CT and daily CBCTs which dominates the deformable registration in the posterior direction. The displacement of the location of the anterior endorectal balloon wall (which is closely followed by the posterior CTV boundary) in the planning CT and in the deformably registered CBCTs, as measured in the sagittal plane, was less than 1 mm. To investigate the quality of the deformable image registration results in soft tissue distant from the endorectal balloon, we used small calculations in the prostate gland or surgical clips in case of postoperatively treated patient as internal landmarks. On purpose, the fractions with largest posterior Hausdorff distance were selected for this analysis. An average residual error of 1.7 mm between the landmarks identified on the planning CT and on the deformably registered CBCT was derived. This is an acceptable accuracy for the described usage.

According to the commonly used margin recipe proposed by van Herk, a posterior PTV margin of 8.8 mm (9.7 mm) is required to ensure a minimum dose to the CTV of 95% for 90% (95%) of our patients. This margin is markedly larger than the 6-mm margin proven to be sufficient for our dataset. A combination of several factors may explain the discrepancy: Most importantly, our data showed that a criterion on the minimum dose is not mandatory to maintain the target EUD$_{3F}$ within tight limits when reasonable cell survival model parameters are chosen. Moreover, time series analysis of the dose at point $P_{worst}$ showed outliers not predicted by normal distributions. Hence, the prerequisites for the computation of the cumulative dose distribution underlying the margin recipe are not fulfilled.

Van Herk’s formula infers the PTV margin for the individual patient from random deviations of the target position and the scatter of the systematic mean deviations over all patients. However, we demonstrated that residual deviations quantified by various spatial and dosimetric parameters differ significantly from patient to patient (Table S3). Applying uniform margins, derived under the inclusion of worst case patients, to the population will be overly conservative for the majority of patients. Our analysis has shown that a 2-mm margin is still sufficient to maintain EUD$_{3F}$ > 90% (95%) in 75% (58.3%) of the patients. When daily image guidance is used, the systematic setup error derived from a patient population is not relevant for the individual patient, instead the daily individual systematic deviation matters. It is reasonable to determine the PTV margin for the

80%–90% of patients with smaller deformations and use larger margins with or without adaptive replanning for the remainder, as identified during the treatment series.

5 | CONCLUSIONS

This analysis of definitive and postoperative radiotherapy of prostate cancer with endorectal balloon demonstrated that dose distributions accumulated over the treatment series are forgiving of considerable residual distortions observed at a frequency below 50% of the fractions. PTV margin calculations at point $P_{worst}$ with largest posterior Hausdorff distance over all fractions are overly conservative because daily online 6-dof IGRT corrects translational and rotational errors such that only residual deformations have to be considered. Studies of this nature help establish a rational basis for online navigation, margin optimization, and treatment adaptation strategies.

CONFLICT OF INTEREST

No conflicts of interest.

AUTHOR CONTRIBUTIONS

Sabine Levegrün and Martin Stuschke conceived and designed the study, collected and analyzed the data, and interpreted the results. Sabine Levegrün drafted the manuscript. Christoph Pöttgen, Konstantinos Xydis, Maja Guberina, and Jehad Abu Jawad contributed to the data acquisition and preparation. All authors revised the manuscript and approved the final version.

REFERENCES

1. Smeenk RJ, van Lin ENJ, van Kollenburg P, McColl GM, Kunze-Busch M, Kaanders JHAM. Endorectal balloon reduces anorectal doses in post-prostatectomy intensity-modulated radiotherapy. Radiother Oncol. 2011;101:465–470.
2. van Lin ENJ, Hoffmann AL, van Kollenburg P, Leer JW, Visser AG. Rectal wall sparing effect of three different endorectal balloons in 3D conformal and IMRT prostate radiotherapy. Int J Radiat Oncol Biol Phys. 2005;63:565–576.
3. van Lin ENJ, Kristinsson J, Philippens MEP, et al. Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys. 2007;67:799–811.
4. Wortel RC, Heemsbergen WD, Smeenk RJ, et al. Local protocol variations for image guided radiation therapy in the multicenter Dutch hypofractionation (HYPRO) trial: Impact of rectal balloon and MRI delineation on anorectal dose and gastrointestinal toxicity levels. Int J Radiat Oncol Biol Phys. 2017;99:1243–1252.
5. Vargas C, Saito AI, Hsi WC, et al. Cine-magnetic resonance imaging assessment of intrafraction motion for prostate cancer patients supine or prone with and without a rectal balloon. Am J Clin Oncol. 2010;33:11–16.
6. Wang KK-H, Vapiwala N, Devile C, et al. A study to quantify the effectiveness of daily endorectal balloon for prostate intrafraction motion management. Int J Radiat Oncol Biol Phys. 2012;83:1055–1063.
26. Meijer GJ, de Klerk J, Bzdusek K, et al. What CTV-to-PTV margins should be applied for prostate irradiation? Four-dimensional quantitative assessment using model-based deformable image registration techniques. *Int J Radiat Oncol Biol Phys.* 2008;72:1416–1423.

27. Liang J, Wu Q, Yan D. The role of seminal vesicle motion in target margin assessment for online image-guided radiotherapy for prostate cancer. *Int J Radiat Oncol Biol Phys.* 2009;73:935–943.

28. Deasy JO, Niemierko A, Herbert D, et al. Methodological issues in radiation dose-volume outcome analyses: summary of a joint AAPM/NIH workshop. *Med Phys.* 2002;29:2109–2127.

29. Ballhausen H, Reiner M, Kantz S, Belka C, Sohn M. The random walk model of intrafraction movement. *Phys Med Biol.* 2013;58:2413–2427.

30. Ballhausen H, Li M, Hegemann NS, Ganswindt U, Belka C. Infrac- tion motion of the prostate is a random walk. *Phys Med Biol.* 2015;60:549–563.

31. Pommer T, Oh JH, af Rosenschold PM, Deasy JO. Simulating intrafraction prostate motion with a random walk model. *Adv Radiat Oncol.* 2017;2:429–436.

32. Orlandini LC, Coppola M, Fulcheri C, Cernusco L, Wang P, Cionini L. Dose tracking assessment for image-guided radiotherapy of the prostate bed and the impact on clinical workflow. *Radiat Oncol.* 2017;12:78.

33. Qin A, Sun Y, Liang J, Yan D. Evaluation of online/offline image guidance/adaptation approaches for prostate cancer radiotherapy. *Int J Radiat Oncol Biol Phys.* 2015;91:1026–1033.

34. Wen N, Glide-Hurst C, Nurushev T, et al. Evaluation of the deformation and corresponding dosimetric implications in prostate cancer treatment. *Med Phys.* 2012;39:5352–5337.

35. Wen N, Kumarasiri A, Nurushev T, et al. An assessment of PTV margins based on actual accumulated dose for prostate cancer radiotherapy. *Phys Med Biol.* 2013;58:7733–7744.

36. Yu J, Hardcastle N, Jeong K, Bender ET, Ritter MA, Tomé WA. On voxel-by-voxel accumulated dose for prostate radiation therapy using deformable image registration. *Technol Cancer Res Treat.* 2015;14:37–47.

37. Moteabbed M, Trofimov A, Kahn FH, et al. Impact of interfraction motion on hypofractionated pencil beam scanning proton therapy and VMAT delivery for prostate cancer. *Med Phys.* 2018;45:4011–4019.

38. Rijkhorst EJ, Lakeman A, Nijkamp J, et al. Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects. *Int J Radiat Oncol Biol Phys.* 2009;75:1254–1260.

39. Broek KK, Mutic S, McNutt TR, Li H, Kessler ML. Use of image registration and fusion algorithms and techniques in radiotherapy: report of the AAPM Radiation Therapy Committee Task Group. No. 132. *Med Phys.* 2017;44:e43–e76.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**Fig. S1** Isotopic Hausdorff distance HDiso determined for every treatment fraction of patients treated with definitive (a) or postoperative (b) radiotherapy, respectively. Posterior Hausdorff distance HDpost per fraction for patients treated with definitive (c) or postoperative (d) radiotherapy, respectively.

**Fig. S2** Shift in anterior-posterior direction assessed through the y-component of the deformation vector at point $P_{worst}$ for every treatment fraction of patients treated with definitive (a) or postoperative (b) radiotherapy, respectively. Positive values indicate a posterior shift. Relative dose $D_{rel}$ at point $P_{worst}$ per treatment fraction for
patients treated with definitive (c) or postoperative (d) radiotherapy, respectively.

**Fig. S3** Cumulative distribution functions of $EUD_{SF}$ for 12 prostate patients. At any specified value of $EUD_{SF}$, the fraction of treatment sessions with a measured $EUD_{SF}$ less than or equal to the specified value is plotted. a) Clinical plans with 6 mm margin. b) Plans with 2 mm margin.

**Fig. S4** Scatter plots of the median value of the distribution of the $gEUD_{a}$-values calculated for every individual treatment fraction of each patient versus $gEUD_{a}$ derived from the accumulated dose distributions. (a) Parameter $a = -20$. (b) Parameter $a = -7$. The plots include both 6 mm and 2 mm CTV-to-PTV margin plans for 12 patients.

**Fig. S5** Time series plots of the posterior Hausdorff distance over all treatment fractions for the four patients with worst HD$_{post}$-distribution (patient 7: definitive radiotherapy, patients 103, 106, and 110: postoperative radiotherapy).

**Table S1** Comparison of prostate cancer patients treated with definitive and postoperative radiotherapy.

**Table S2** Parameters characterizing the distributions of the isotropic and posterior Hausdorff-distances over the treatment series for prostate patients treated with definitive (patients 1-12) or postoperative radiotherapy (patients 101-112), respectively.

**Table S3** Number of fractions with selected spatial and dosimetric parameters exceeding a given threshold value. The numbers in brackets identify the corresponding patient(s).

**Table S4** Parameters characterizing the distributions of the deformation vector components over the treatment series for prostate patients treated with definitive (patients 1-12) or postoperative radiotherapy (patients 101-112).

**Table S5** Parameters summarizing the distributions of the anterior-posterior deformation vector component $y$ and of the dose deviations with respect to the treatment plan at different points of interest within the planned CTV.